Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplication
Project Number5UM1AI069463-19
Contact PI/Project LeaderSANNE, IAN MATTHIAS Other PIs
Awardee OrganizationWITS HEALTH CONSORTIUM (PTY), LTD
Description
Abstract Text
7. Project Summary/Abstract
The Wits HIV Research Group Clinical Trials Unit (WHRG CTU) under the joint PI Leadership of Ian Sanne
and Helen Rees, includes four experienced pleuripotent Clinical Research Sites (CRSs), namely the Wits
Helen Joseph Hospital CRS (Dr Sharlaa Badal-Faesen), The Wits RHI Shandukani Maternal and Child CRS
(Dr Lee Fairlie), Wits RHI Hillbrow Health Precinct Ward 21 CRS (Prof. Sinead Delaney-Moretlwe) and the
Wits RHI Research Centre (Dr Thesla Palanee-Phillips). These four CRSs have capacity to conduct clinical
trials across all four NIH Networks, the ACTG, IMPAACT, HPTN and VTN.
The CTU’s research agenda includes HIV treatment, HIV-associated infections and HIV-related cancers; HIV
prevention; TB treatment and prevention (including MDR-TB) and Hepatitis. The CTU conducts research
across all key populations, including adolescent girls and young women, men who have sex with men,
transgender populations and female sex workers; as well as vulnerable populations such as neonates, infants,
older children, pregnant and breastfeeding women. The CTU has capacity to conduct Investigational New Drug
(IND) level trials including phase I/II/II trials, blinded and unblinded randomized trials, across a wide range of
products including oral products for treatment and prevention; vaccines for infants, children, adolescents,
pregnant women and adults; injectable long acting antiretrovirals for treatment and prevention; monoclonal
antibody infusions and microbicides. The expertise, facilities and specialized equipment at each CRS results in
the sites conducting these studies at a high level of quality and efficiency. The CTU has in-house laboratory
capacity and contracts external laboratories to perform testing to the required Network standards.
The four sites are situated in Johannesburg, South Africa’s bustling urban centre and populations included in
the CTU research are recruited within Johannesburg, using a targeted approach appropriate for each, and
ensuring that hard-to-engage people who may be at highest risk are not excluded. This requires facility- and
community-based recruitment and the CTU has a formalized approach, for community engagement across all
relevant populations based on good participatory practice principles.
The CTU has substantial experience and expertise within all components including but Pharmacy, Regulatory
Processes, Data Management, Quality Management, Training and Mentoring and although the four CRSs are
distinct, the CTU optimizes efficiencies and collaboration across all CRSs. Experience related to specific
populations is shared within the CTU, but also externally locally in South Africa, Regionally and Internationally.
The CTU has had over 10 successful IND audits and inspections FDA, EMEA and SAHPRA; and numerous
successful PPD and sponsor inspections.
Public Health Relevance Statement
8. Project Narrative
The Wits HIV Research Group Clinical Trials Unit (WHRG CTU) consists of four pleuripotent Clinical Research
Sites-The Wits Helen Joseph Hospital CRS, The Wits RHI Shandukani Maternal and Child CRS, Wits RHI
Hillbrow Health Precinct Ward 21 CRS and the Wits RHI Research Centre. The WHRG CTU research agenda
includes HIV treatment, HIV-associated infections and HIV-related cancers; HIV prevention; TB treatment and
prevention (including MDR-TB) and Hepatitis. The CTU conducts research across key populations, including
adolescent girls and young women, men who have sex with men, transgender populations and female sex
workers; as well as vulnerable populations such as neonates, infants, older children, pregnant and
breastfeeding women to a high standard of quality, which has been recognized locally and internationally.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AIDS clinical trial groupAIDS preventionAdolescentAdultBlindedBreast FeedingChildChildhoodClinical ResearchClinical TrialsClinical Trials Cooperative GroupClinical Trials NetworkClinical Trials UnitCollaborationsCommunitiesConduct Clinical TrialsContractsDataDevelopmentElementsEnsureEpidemicEquipmentEthicsFemale AdolescentsFundingGood Clinical PracticeHIVHIV prevention trials networkHIV/AIDSHealthHepatitisHospitalsIndividualInfantInfectionInfrastructureInfusion proceduresInjectableInstitutionInternationalInternational Maternal Pediatric Adolescent AIDS Clinical TrialsInvestigational DrugsJointsLaboratoriesLeadershipLegalMalignant NeoplasmsMedicineMentorsMonoclonal AntibodiesMorbidity - disease rateMultidrug-Resistant TuberculosisNational Institute of Allergy and Infectious DiseaseOccupational activity of managing financesOffice of Administrative ManagementOralPersonsPharmacy facilityPhasePoliciesPopulationPregnant WomenPreventionPrevention ResearchProceduresProcessReapplicationResearchResearch ActivityResearch InfrastructureResearch PersonnelSamplingSiteSouth AfricaStructureTestingTherapeuticTrainingTuberculosisU-Series Cooperative AgreementsUnited States National Institutes of HealthVTN geneVaccinesVulnerable PopulationsWitWomanantiretroviral therapyclinical centerclinical developmentclinical research sitecommunity engagementcomorbiditydata managementexperiencefemale sex workerhigh riskhigh standardmen who have sex with menmicrobicidemortalityneonatepatient populationpopulation basedpregnantrandomized trialrecruitstudy populationtransgendertransmission processtreatment researchtuberculosis treatmentvaccine trialwardyoung woman
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
639391218
UEI
KNNNGEN9MQB8
Project Start Date
15-March-2007
Project End Date
21-March-2025
Budget Start Date
01-December-2024
Budget End Date
21-March-2025
Project Funding Information for 2025
Total Funding
$943,730
Direct Costs
$873,824
Indirect Costs
$69,906
Year
Funding IC
FY Total Cost by IC
2025
National Institute of Allergy and Infectious Diseases
$943,730
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5UM1AI069463-19
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5UM1AI069463-19
Patents
No Patents information available for 5UM1AI069463-19
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5UM1AI069463-19
Clinical Studies
No Clinical Studies information available for 5UM1AI069463-19
News and More
Related News Releases
No news release information available for 5UM1AI069463-19
History
No Historical information available for 5UM1AI069463-19
Similar Projects
No Similar Projects information available for 5UM1AI069463-19